Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

Last updated: October 20, 2014
Sponsor: Nanfang Hospital of Southern Medical University
Overall Status: Trial Status Unknown

Phase

2

Condition

Non-small Cell Lung Cancer

Treatment

N/A

Clinical Study ID

NCT02272127
NFEC-2014-069
  • Ages > 18
  • All Genders

Study Summary

Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations are exquisitely sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) which is widely used in advanced patients. Whether treatment with EGFR-TKIs improves outcomes in patients with resected NSCLC harboring EGFR mutations is still under investigated. This study aims to observe and compare the efficacy and safety of intercalated combination of chemotherapy plus icotinib in patients undergoing resection of EGRF mutation-positive non-small cell lung cancer stagingⅠB (with high risk factor) to ⅢA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients undergoing completely resection of EGRF mutation-positive NSCLC

  • Staging ⅠB (with high risk factor) to ⅢA

  • PS＜2

  • Adequate hematological, biochemical and organ functions.

Exclusion

Exclusion Criteria:

  • Systemic anticancer therapy prior to surgery, other malignancies before or during thestudy, any unstable illness, women who were pregnant or lactating.

Study Design

Total Participants: 100
Study Start date:
July 01, 2014
Estimated Completion Date:
July 31, 2019

Connect with a study center

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong 510515
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.